Cargando…
Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
BACKGROUND: Mutations in the ABL kinase domain and SH3-SH2 domain of the BCR/ABL gene and amplification of the Philadelphia chromosome are the two important BCR/ABL dependent mechanisms of imatinib resistance. Here, we intended to study the role played by TKI, imatinib, in selection of gene mutation...
Autores principales: | Vaidya, Shantashri, Vundinti, Babu Rao, Shanmukhaiah, Chandrakala, Chakrabarti, Prantar, Ghosh, Kanjaksha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309587/ https://www.ncbi.nlm.nih.gov/pubmed/25629972 http://dx.doi.org/10.1371/journal.pone.0114828 |
Ejemplares similares
-
Deletion of ABL/BCR on der(9) associated with severe basophilia
por: Vaidya, Shantashri, et al.
Publicado: (2011) -
Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020) -
Octaploidy in idiopathic thrombocytopenia purpura: Is it incidental or causal?
por: Vaidya, Shantashri, et al.
Publicado: (2012) -
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019) -
Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
por: Watanabe, Kousuke, et al.
Publicado: (2020)